Pretax income is the income that a company earns before paying income taxes. Processa Pharmaceuticals's pretax income for the
three
months ended in Dec. 2024 was $-2.73 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-11.85 Mil.
Processa Pharmaceuticals's pretax margin was %.
During the past 13 years, Processa Pharmaceuticals's highest Pretax Margin was -2639.82%. The lowest was -6740.00%. And the median was -4689.91%.
Processa Pharmaceuticals Pre-Tax Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Processa Pharmaceuticals's Pre-Tax Income
For the Biotechnology subindustry, Processa Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Processa Pharmaceuticals's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Processa Pharmaceuticals's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Processa Pharmaceuticals's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.85 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Processa Pharmaceuticals (NAS:PCSA) Pre-Tax Income Explanation
Processa Pharmaceuticals's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as
During the past 13 years, Processa Pharmaceuticals's highest Pretax Margin was -2639.82%. The lowest was -6740.00%. And the median was -4689.91%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Processa Pharmaceuticals Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Processa Pharmaceuticals's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PCSA has been successfully added to your 